$Redhill Biopharma (RDHL.US)$RedHill Biopharma Announced Results From New In Vivo Studies Of Opaganib For Gastrointestinal Acute Radiation Syndrome, Undertaken As Part Of The U.S. Government's Radiation And Nuclear Countermeasures Program Contract That Further Confirms Opaganib's Protective Activity In Animal Models Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass ...
$Redhill Biopharma (RDHL.US)$ Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced DevelopmentTuesday, 10th December at 7:00 am Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass casualty nuclear or radiological incident There are currently no known approved therapies for gas...
Note: This seems to be a long list. The rationale is that I al focused on at least 20% gains and not just after bangers. My trading style is to compound those 10-15-20-30% earnings and roll all profit rather than waiting for runners everyday. If runners appear, then I’ll grab it as well. Each has his own style earning. $Damon Inc (DMN.US)$Can be my PM gapper. Low float EV stock. IPO las...
Trytosaveabit
:
As you know I’ve been waiting for this 510 clearance! I know most don’t like it! And admittedly the chart and volume are not looking good! Hehehe! But I really like, have like and continue to like MOVE! Hehehe! People don’t realize just how superior this is over the junk you can just buy on Amazon! Hehehe
$Redhill Biopharma (RDHL.US)$ RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court Monday, 2nd December at 7:00 am RedHill has been awarded a judgment of approximately $8 millionplus costs in a summary judgment by the New York Supreme Court in its legal proceedings against Kukbo Co. Ltd The Court dismissed the entirety of Kukbo's counterclaims, ruling in favor of RedHill's demonstrated good faith commitment to the spirit and the letter of the ag...
$Redhill Biopharma (RDHL.US)$ RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041 New U.S. patent issued covering the identification of a novel biomarker of coronavirus pneumonia (≤60% fraction of inspired oxygen (FiO2)) prognostic for potential opaganib efficacy in treating COVID-19, valid through 204 Published post-hoc data from opaganib's Phase2/3 study showed that patients with ≤60% FiO2 levels had better outcomes after 14 days' opaganib treatment (n=117) comp...
Redhill Biopharma Stock Forum
Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass ...
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced DevelopmentTuesday, 10th December at 7:00 am
Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass casualty nuclear or radiological incident
There are currently no known approved therapies for gas...
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
Monday, 2nd December at 7:00 am
RedHill has been awarded a judgment of approximately $8 millionplus costs in a summary judgment by the New York Supreme Court in its legal proceedings against Kukbo Co. Ltd
The Court dismissed the entirety of Kukbo's counterclaims, ruling in favor of RedHill's demonstrated good faith commitment to the spirit and the letter of the ag...
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
New U.S. patent issued covering the identification of a novel biomarker of coronavirus pneumonia (≤60% fraction of inspired oxygen (FiO2)) prognostic for potential opaganib efficacy in treating COVID-19, valid through 204
Published post-hoc data from opaganib's Phase2/3 study showed that patients with ≤60% FiO2 levels had better outcomes after 14 days' opaganib treatment (n=117) comp...
No comment yet